Stable Expression of Human Aromatase Complementary DNA in Mammalian Cells: A Useful System for Aromatase Inhibitor Screening1

Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening.

A mammalian cell expression plasmid, pH beta-Aro, containing the human placenta aromatase complementary DNA was constructed. The prepared plasmid was used to transfect breast cancer cells (MCF-7), noncancerous breast cells (HBL-100), and Chinese hamster ovary cells by a stable expression method. While the maximum velocities for aromatase expressed in three types of cells were different (10-201 ...

P-227: Functional Analysis of The I.a,I.b, I.c and I.d (PII) Promoters of CYP19 (aromatase) Gene in Granulosa Cells of Polycystic Ovaries Patients and The Role of Letrozole and Antisensearom on CYP19 Gene Expression Inhibition

Background: The key enzyme of estrogen biosynthesis, aromatase cytochrome P450,is encoded by the CYP19 gene.CYP19 plays an important role in the development,function,an regulation of the female reproduction cycle. Thus, it is the potential candidate gene affecting fertility performance in human. CYP19 transcripts are expressed mainly in the ovary,testes,breast,adipose tissue and brain. Tissue e...

P-200: Effects of The ?3 Fatty Acid Eicosapentaenoic Acid on PPARa and Aromatase in Human Granulosa Cells

P-11: Differential Expression of mRNA Aromatase in Ejaculated Spermatozoa from Infertile Men in Relation to either Asthenozoospermia or Teratozoospermia

Background Estrogens biosynthesis in ejaculated spermatozoa is an autonomous process that may influence sperm functions. The purpose of this study was to evaluate the relationship between the expression of aromatase, sperm quality and seminal neutral α–glucosidase marker in semen of Tunisian infertile men. MaterialsAndMethods Fifty seven men were investigated: they were composed of two groups: ...

P-207: Pharmacogenetic Study of CYP19A1 (Aromatase) in Ovarian Induction in Iranian Polycystic Ovarian Syndrome Patients

Background: Hyper-androgenemia is one of the main clinical features of polycystic ovarian syndrome (PCOS). Letrozol is an aromatase inhibitor drug, which is co-administered with gonadotropins in most cases of PCOS, to improve ovulation. Aromatase has a critical role in catalyzing the conversion of androgens to estrogens and is responsible for keeping the homeostatic balance between them. Hence ...